Pulse Biosciences, Inc. (NASDAQ:PLSE) traded up 8.2% during trading on Thursday . The company traded as high as $21.62 and last traded at $21.62. 120 shares traded hands during trading, a decline of 100% from the average session volume of 111,170 shares. The stock had previously closed at $19.99.
Several brokerages have recently weighed in on PLSE. Zacks Investment Research upgraded shares of Pulse Biosciences from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a research note on Friday, August 13th. Stephens began coverage on shares of Pulse Biosciences in a research report on Monday, July 26th. They issued an “overweight” rating and a $28.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $46.00 target price on shares of Pulse Biosciences in a research report on Tuesday, August 10th.
The business’s 50-day moving average price is $22.21 and its two-hundred day moving average price is $20.86. The firm has a market cap of $686.86 million, a price-to-earnings ratio of -9.91 and a beta of 1.63.
Large investors have recently bought and sold shares of the stock. BlackRock Inc. raised its stake in Pulse Biosciences by 7.6% during the first quarter. BlackRock Inc. now owns 950,299 shares of the company’s stock valued at $22,503,000 after buying an additional 67,501 shares in the last quarter. State of Wisconsin Investment Board bought a new position in Pulse Biosciences during the first quarter worth $246,000. Royal Bank of Canada boosted its holdings in Pulse Biosciences by 87.7% in the first quarter. Royal Bank of Canada now owns 1,946 shares of the company’s stock worth $46,000 after purchasing an additional 909 shares during the period. Alliancebernstein L.P. increased its stake in Pulse Biosciences by 4.6% during the second quarter. Alliancebernstein L.P. now owns 22,849 shares of the company’s stock valued at $375,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Pulse Biosciences by 141.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 21,621 shares of the company’s stock worth $512,000 after buying an additional 12,664 shares during the last quarter. Institutional investors and hedge funds own 10.71% of the company’s stock.
Pulse Biosciences Company Profile (NASDAQ:PLSE)
Pulse Biosciences, Inc operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling.
Featured Story: What is a stock buyback?
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.